O utcome from experimental stroke is linked to a complex intertwining schema of pro-oxidant mechanisms. Both NO and superoxide anion are thought to be essential actors in oxidative injury during cerebral ischemia. Neuronal overproduction of NO has been consistently postulated to occur in the ischemic brain, leading to the death of neighboring cells. In part, NO toxicity is explained as a consequence of its propensity to react with superoxide at extremely fast rates and form the potent oxidant peroxynitrite (ONOO Ϫ ). ONOO Ϫ is lipid soluble and has a wide assortment of potential oxidation targets, including proteins, RNA, and DNA. 1, 2 Some of the neurotoxicity of ONOO Ϫ results from depression of mitochondrial respiration 3, 4 and from DNA strand breakage, See Editorial Comment, page 2691 which stimulates energy-consuming DNA repair processes involving poly(ADP-ribose) polymerase. 5, 6 Pharmacological inhibitors of NO synthase (NOS) or genetic deficiency of the neuronal enzymatic isoform (nNOS) reduces NO/ONOO Ϫ toxicity and improves cell survival in many experimental paradigms (References 7 and 8; for review, see Reference 9) . In turn, superoxide anion has long been recognized as a key oxidant species in brain injury. Numerous sources of enhanced superoxide production have been identified, including anoxic mitochondria, activated microglia and neutrophils, and membrane-bound oxidases. Therapeutic maneuvers de-signed to limit intraischemic increases in intracellular superoxide concentration also achieve neuroprotection (for review, see References 10 and 11) . Compared with nontransgenic mice, mice overexpressing human CuZn superoxide dismutase (hSOD1) sustain less brain injury after middle cerebral artery occlusion (MCAO) 12 ; extracellular superoxide dismutase (SOD)-overexpressing strains are protected in a similar manner. 13 Furthermore, overexpression of manganese SOD, the mitochondrial isoform, reduces NO and ONOO Ϫ toxicity in vitro. 14, 15 Although it is clear that reactions involving NO or superoxide are activated in the ischemic brain, it is not known whether these molecules act within parallel pathological pathways or as coreagents in a common toxic reaction. Furthermore, it has been difficult to independently manipulate these agents in the intact brain or to determine relative contributions of NO release and superoxide generation in an animal model of neuroinjury. We hypothesized that both NO and superoxide must be present in sufficient amounts and in proximate tissue compartments if ONOO Ϫ synthesis is to be fueled. If either NO or superoxide concentration is largely ablated, then lower levels of ONOO Ϫ could result, with decreased injury to intracellular targets. Under these conditions, salvage of tissue from injury would not be different, regardless of whether NO, superoxide, or both are reduced. Alternatively, enhanced SOD1 activity through non-NO overlapping mechanisms could directly benefit the injured brain. Under these conditions, enhanced superoxide scavenging might benefit the brain in a manner additive or synergistic to the loss of neuronal NO. We used a set of transgenic mouse strains to explore these interlocking mechanisms in vivo: nNOS-deficient (nNOSϪ/Ϫ) mice, hSOD1 overexpressors (hSOD1ϩ/Ϫ mice), and a novel strain in which both mutations were combined (nNOSϪ/Ϫ,hSOD1ϩ/Ϫ mice). The aim was to determine whether nNOSϪ/Ϫ,hSOD1ϩ/Ϫ mice exhibit improved function and smaller tissue injury after MCAO compared with mice with a single mutation.
Materials and Methods
The present study was conducted in accordance with the National Institutes of Health guidelines for the care and use of animals in research and under protocols approved by the Animal Care and Use Committee of the Johns Hopkins University. Three age-and weightmatched transgenic strains were studied, and each was compared with its genetically matched wild-type strain (WT). The animal groups were as follows: (1) homozygous nNOS-null mice (nNOSϪ/Ϫ, founder stock 16 ; nϭ33 total, 22 males and 11 females); (2) heterozygous hSOD1 overexpressors (hSODϩ/Ϫ, founder stock 17 ; nϭ18 total, 10 males and 8 females); (3) a novel nNOSdeficient hSOD1-overexpressing mutant strain bred on an nNOSϪ/Ϫ background (nNOSϪ/Ϫ,hSOD1ϩ/Ϫ; nϭ25 total, 11 males and 14 females); (4) C57Bl/6 WT control mice for the nNOSϪ/Ϫ and double-mutant strains (nϭ20 total, 11 males and 9 females); and (5) C57Bl/6J WT control mice for the hSODϩ/Ϫ strain (nϭ34 total, 21 males and 13 females). Because the background strain for the hSODϩ/Ϫ mice was not genetically identical to that of the nNOSϪ/Ϫ and double-mutant mice, 2 groups of WT control mice were used. The genotype of all animals was determined by polymerase chain reaction (PCR) as described previously. 16 nNOSϪ/Ϫ mice were produced on a purebred C57Bl/6 background as previously described. 16, 18 Since their development, the nNOSϪ/Ϫ mice have been continually outbred to WT C57Bl/6 (Charles River) to avoid potential effects of strain or inbreeding. The transgenic mice had been backcrossed to the WT mice Ϸ8 times at the time of the present study. Because nNOSϪ/Ϫ mice were therefore Ͼ99% genetically identical to WT mice, the C57Bl/6 mice from Charles River were used as the nNOSϪ/Ϫ control cohort. The hSOD1-overexpressing mice were produced as previously described in 1995. 17 These animals were originally produced in the C57Bl/ 6JϫHeJ hybrid strain, initially backcrossed to this same hybrid, and then subsequently bred to the C57Bl/6J strain (Charles River). The level of hSOD1 to endogenous mouse SOD1 activity in brain is 8:1, with a transgene product distribution quite similar to that of endogenous mouse enzyme. 17 The hSOD1 transgenic mice have been extensively backcrossed to the C57Bl/6J WT mice, resulting in near genetic confluence. Therefore, this WT mouse was used in control comparisons with the hSOD1 mutant.
To develop the novel double mutants, hSOD1ϩ/Ϫ mice were bred to WT C57/Bl6 mice, and the colony was screened by use of one PCR primer common for mouse and human SOD (5Ј-GTT ACA TAT AGG GGT TTA CTT CAT AAT CTG-3Ј) and human/mouse SOD primers (5Ј-CAG CAG TCA CAT TGC CCA (A/GGT CTC CAA CAT G-3Ј). The presence of mouse SOD on PCR served as an internal PCR control, because all mice expressed mouse CuZn SOD. Female hSOD1ϩ/Ϫ mice were then bred to nNOS Ϫ/Ϫ male mice, creating nNOS heterozygotes, some of which also overexpressed SOD (nNOSϩ/Ϫ,SODϩ/Ϫ mice) These double heterozygotes were then bred to produce nNOS-null SOD-overexpressing mice (nNOSϪ/Ϫ,SODϩ/Ϫ mice). This new colony was screened by using PCR primers for nNOS and SOD as described above. The PCR primers were designed to confirm the absence of nNOS (5Ј-CTT TCA TCT CTG CTT TGG CTG G-3Ј, 5Ј-ATC TCA GAT CTG ATC CGA G-3Ј) and the presence of neomycin (5Ј-CAC CAT GAT ATT CGG CAA GCA G-3Ј, 5Ј-TGG AGA GGC TAT TCG GCT ATG AC-3Ј).
Ischemic Model
Mice were anesthetized with 1% to 1.2% halothane in oxygenenriched air by face mask. The femoral artery was cannulated for measurement of arterial blood gases and blood pressure. Rectal temperature was controlled at near 37°C throughout the experiment with heating lamps and water pads for all animals. After baseline arterial blood gas measurement, permanent unilateral MCAO was performed with use of an intraluminal filament-insertion technique. The proximal common carotid artery was ligated, and a 6-0 nylon monofilament was inserted and advanced into the internal carotid artery to a distance of 6 mm from the internal carotid/pterygopalatine artery bifurcation to the suture tip. Intraischemic arterial blood pressure and blood gases were determined after occlusion, then the catheters removed, and anesthesia was discontinued. Neurological deficit was confirmed in each animal at 1 hour of occlusion. Neurological deficit was scored as follows: 0, no deficit; 1, forelimb weakness; 2, circling to affected side; 3, unable to bear weight on affected side; and 4, no spontaneous motor activity. If no deficit was observed, the animal was removed from the study cohort. After 18 hours of MCAO, neurological status was again scored, and the brain was harvested for analysis. Infarction volume was determined by 2,3,5-triphenyltetrazolium staining in five 2-mm slices and evaluated via digital planimetry.
Statistical Analysis
All data are expressed as meanϮSE. Physiological variables and histology were analyzed by 1-way ANOVA with a post hoc Newman-Keuls test to correct for multiple comparisons and determine differences between transgenic strains. Postischemic neurological scores were analyzed by the Mann-Whitney U test. Statistical comparisons were made between each transgenic strain and its appropriate WT control group. Because SOD1 overexpressors were originally developed from C57Bl/6J mice, this additional cohort was incorporated into the study design. For simplicity, we have presented the data analysis so that the nNOSϪ/Ϫ and double-mutant mice were compared with their commonly held WT background. Alternatively, when data from the nNOSϪ/Ϫ and double-mutant mice were statistically compared with either WT cohort of the study, the same result was obtained. Last, animals of both sexes were used in each group. Accordingly, a post hoc analysis of histology was carried out to determine whether there were sex differences in infarction within each genetic group and whether the effect of the mutation was the same in both males and females. For this, a 1-way ANOVA with a Newman-Keuls test was used to examine total infarction volume for each genetic group, separated by sex. A 2-way ANOVA with a Newman-Keuls test was used to analyze effect of the sex-matched transgenic strain (between-group comparison) on infarction volume by brain slice (within-group comparison).
Results
Arterial blood pressure, body temperature, and blood gas composition before and during MCAO remained within physiological range in all groups (Table) . In general, intraischemic values were comparable among transgenic groups. Figure 1 summarizes total hemispheric infarction volume in each animal cohort, expressed as a percentage of the contralateral hemisphere. First, each genetic modification reduced stroke relative to the WT mouse. Infarction volume was smaller in nNOSϪ/Ϫ mice (80Ϯ6 mm 3 ) and in the double-mutant mice (49Ϯ6 mm 3 ) than in the WT control mice (114Ϯ7 mm 3 ). Similarly, injury was reduced in hSOD1ϩ/Ϫ mice (52Ϯ7 mm 3 ) compared with their background WT mice (95Ϯ5 mm 3 ) . Neurological scores at 18 hours reflected these histological differences. Consistent with the severity of the ischemic insult, distinct functional deficits were observed in all animals, except for 2 females within the hSOD1ϩ/Ϫ group, who were accorded a score of 0. Outcome score was improved in nNOSϪ/Ϫ (2.5Ϯ0.2) and doublemutant (1.9Ϯ0.1) mice compared with WT mice (3.1Ϯ0.2). Similarly, outcome was improved in hSOD1ϩ/Ϫ (1.6Ϯ0.2) compared with WT (3.0Ϯ0.1) mice. Second, hSOD1 overexpression had a larger effect on infarction volume than did nNOS deficiency. Mean infarction volume was 46% of the contralateral hemisphere in nNOSϪ/Ϫ mice compared with 30% in hSOD1ϩ/Ϫ transgenic mice. However, neurological scores were not different between the nNOSϪ/Ϫ and hSOD1 groups. Third, damage in the double-mutant mice was not reduced relative to each single mutation. Although infarction volume in double-mutant mice was less than that observed in mice with the single mutation (nNOSϪ/Ϫ), the injury in double-mutant mice was not different from that in hSOD1-overexpressing mice. The neurological outcome score again paralleled improvements in tissue injury. Although doublemutant animals scored better than did the nNOSϪ/Ϫ animals after MCAO, the outcome scores were the same in doublemutant (1.9Ϯ0.1) and hSOD1-overexpressing (1.6Ϯ0.2) animals.
We also evaluated the effect of each mutation separately in male and female animals on a post hoc basis to identify potential sex bias in the study. There was no absolute difference in infarction between males and females within any genetic group. However, there was one large sex difference when the protection provided by the mutation was assessed relative to WT control animals. Whereas male Hemispheric infarction volume expressed as percentage of contralateral nonischemic hemisphere. Three transgenic species of mice were studied: (1) background C57Bl/6 WT for nNOSϪ/Ϫ and double-mutant mice (nϭ20 total, 11 males and 9 females), (2) nNOSϪ/Ϫ mice (nϭ33 total, 22 males and 11 females), (3) nNOSϪ/Ϫ,hSOD1ϩ/Ϫ mice (nϭ25 total, 11 males and 14 females), (4) hSOD1ϩ/Ϫ mice (nϭ18 total, 10 males and 8 females), and (5) 
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nNOSϪ/Ϫ animals exhibited a clear reduction in histological damage compared with male WT animals (Figure 2A ), the female animals did not benefit from nNOS deficiency ( Figure  2B ). However, the females did benefit from hSOD1 overexpression or the double mutation. In hSOD1 overexpressors, infarction volume was reduced in both sexes relative to their respective WT (Figure 3 ), although the effect was less robust in male hSOD1ϩ/Ϫ animals ( Figure 3B ). Both male and female nNOSϪ/Ϫ,hSOD1ϩ/Ϫ mice sustained equivalent total infarction volumes, and each sex was protected compared with its respective WT (Figure 4) . In view of a potential for sex bias in the nNOSϪ/Ϫ group, we repeated the analysis of infarction volume for this group when limited to only male animals. Infarction volume remained smaller in male nNOSϪ/Ϫ mice (76Ϯ8 mm 3 , nϭ22) compared with WT control mice (125Ϯ11 mm 3 ).
Discussion
The present study presents 2 main findings. First, doublemutant mice of both sexes that are nNOS deficient and overexpress hSOD1 sustain reduced tissue infarction relative to their genetically matched WT counterparts. However, each single mutation is not equipotent in reducing ischemic injury in vivo, because the efficacy of reducing nNOS can be increased by hSOD1 availability. Conversely, SOD1 overexpression is equally efficacious in the presence or absence of neuronal NO generation, suggesting that superoxide generation contributes more to damage than does NO toxicity after severe ischemia. Therefore, CuZn SOD may scavenge superoxide within cellular compartments or through biochemical pathways that are not restricted to, and may be distinct from, neuronal NO/superoxide reaction and ONOO Ϫ synthesis. Second, these experiments demonstrate a novel sex-based difference in stroke pathophysiology. Whereas nNOS null mice are protected in experimental stroke, as previously reported, this protection appears to be limited to the male and is not demonstrated in the female. Furthermore, sex bias in stroke outcome was not generalized to all transgenic strains in the present study. This apparent specificity could suggest that fundamental neuronal NO mechanisms of ischemic injury are redirected in the female mutant during cerebral ischemia. The double-mutant strain was constructed to evaluate conditions in which both neuronal NO and superoxide levels are theoretically optimized for ischemic neuroprotection. We reasoned that if both NO and superoxide were requisite as coreagents in ONOO-formation, then no additional effect would be observed by a combined reduction of both radical species. For example, a single previous study used the nNOS inhibitor 7-nitroindazole as a means of further reducing injury after reversible MCAO (60 minutes) in SOD1-overexpressing mice. No additive relationship was observed. 19 Alternatively, coproduction of NO and superoxide could enhance the toxicity of NO in an unanticipated manner, such as through peroxide generation. 20 In the present study, we show that hSOD1 overexpression does add to the protection offered by nNOS deficiency, nearly doubling the reduction observed in nNOSϪ/Ϫ mice relative to their WT counterparts. It seems unlikely that the quenching of ONOO Ϫ resulting from the small residual NO generation known to occur in nNOSϪ/Ϫ mice could account for this substantial reduction of infarction size. Alternatively spliced forms of nNOS (nNOS␤ and nNOS␥) 21, 22 persist in the transgenic mice, which do not use exon 2 for transcription (ie, the site of stop codon insertion used to create the nNOSϪ/Ϫ mutant). These splice forms, particularly nNOS␤, likely account for the small amount of residual (5% to 10%) NOS activity measured in the mice. 14, 23 The functional consequence of this residual NOS activity is not known; however, 3-nitrotyrosine, a biochemical marker for ONOO Ϫ formation, is undetectable by immunocytochemistry in the nNOSϪ/Ϫ brain, even after MCAO. 24 Therefore, residual neuronal NO production in nNOSϪ/Ϫ mice could not account for a further reduction of infarction in the double-mutant mice. A more reasonable explanation is that the robust added protection provided by SOD1 overexpression on an nNOSϪ/Ϫ background represents important parallel radical-scavenging mechanisms that are not tightly linked to reduction of neuronal NO/ONOO Ϫ . One possibility is that ONOO Ϫ synthesis is localized largely to ischemic mitochondria, a major subcellular source of reactive oxygen species and site of exaggerated oxidative stress. If so, then manganese SOD may be the dominant scavenger, leaving cytoplasmic SOD1 poised to derail other sources of oxidant injury.
The benefit of the double mutation was remarkably equal to that achieved with the simple hSOD1ϩ/Ϫ phenotype. The known mechanisms of protection by SOD are extensive, including reduced sensitivity to kainic acid-induced seizures and constitutively enhanced GABA-ergic neurotransmission, 25 protection of mitochondrial respiratory function 26 and blood-brain barrier integrity, 27 preservation of other endogenous antioxidant moieties such as glutathione, 12 and preservation of apurinic/apyrimidinic endonuclease expression and subsequent DNA fragmentation. 28 Interactions with endothelial NOS (NOS 3) may be important if SOD overexpression enhances the effective half-life of NO by dismutating superoxide to hydrogen peroxide. In addition, SOD has novel actions unrelated to superoxide dismutation and can directly enhance free NO production from NOS-catalyzed L-arginine oxidation. 29 If increased NO release or enhanced superoxide scavenging results in greater NO availability within the vasculature, then improved perfusion could lead to tissue salvage in the stroke penumbra. For example, treatment with a nonspecific NOS inhibitor such as N G -nitro-L-arginine methyl ester abolishes the tissue protection ordinarily observed in SOD1-overexpressing mice after MCAO. 19 We did not measure cerebral blood flow in these experiments and so cannot comment on blood flow-associated mechanisms of protection. Furthermore, although the middle cerebral artery was permanently occluded in all animals, leading to a distinct neurological deficit, residual ischemic blood flow could have been different among the 3 transgenic species at any point within the 18 hours of occlusion.
The present investigation was not constructed to prospectively evaluate sex differences in the various transgenic strains. However, in view of increasing reports of sex-linked differences in outcome from neuroinjury, we studied large cohort sizes to ensure a reasonably equivalent male-to-female animal ratio. Female animals have been shown to sustain reduced stroke damage relative to males in rats, 30 gerbils, 31 and mice, 32 and this protection is linked to female sex steroids, particularly estrogen (for review, see Reference 33). 
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The present finding that female mice do not benefit from nNOS deficiency is one of the first demonstrations of a sex-based difference in a fundamental cellular mechanism of cell injury. Further experiments are needed to fully understand this observation and to determine whether the finding is replicated in reversible MCAO or other ischemic models. If estrogen (or progesterone) is implicated in this surprising result, it remains to be shown. If so, then the lack of nNOS-mediated neuroprotection in females may suggest that female sex steroids alter ischemic injury cascades at a point upstream from nNOS activation. Alternatively, estrogen and/or progesterone may protect the brain by a mechanism that parallels the genetic "blockade" of neuronal NO toxicity. Recent work indicates that female mice are also not protected by genetic deficiency in inducible NOS after permanent MCAO, unlike male mice. 32 Interactions between sex steroids and NO toxicity could be quite complex because estrogen alters the expression of endothelial NOS 34, 35 and inducible NOS. 36, 37 In contrast, both male and female mice benefit from hSOD1 overexpression or the double mutation during permanent focal ischemia. These results confirm many previous reports in male mutants with global cerebral ischemia 38 and with reversible, 10, 11, 19 but not permanent, MCAO. 39 There are a large number of methodological differences between the present experiments and this earlier report, 39 including differing WT backgrounds (C57Bl/6J versus CD-1) and methods of transgenic strain development, duration of MCAO (18 versus 24 hours), size of occlusive monofilament (5.0 versus 6.0), and analytic methods for correction of edema. It should also be noted that the largest difference is that the study of Chan et al 39 was conducted in all male animals. Even in the present study, in which a significant effect could be seen, the protection in male hSOD1 mice was not striking compared with that observed in female hSOD1 mice. It may be that native SOD1 activity is lower in female mice; hence, overexpression is highly beneficial in the female. Further studies are needed for exploration of this issue and for comparative quantification of hSOD1 transgene expression products in male versus female mutants.
In conclusion, stroke damage in a novel strain of nNOSdeficient hSOD1-overexpressing mice was equivalent to that achieved with the single hSOD1-overexpressing mutation. SOD1 overexpression reduces acute stroke damage by mechanisms not restricted to nNOS generation.
